Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
180 participants
OBSERVATIONAL
2012-03-31
2016-04-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Pacemaker mode programming
High grade AV-block
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* implanted cardioverter/defibrillator or pacemaker
* negative pregnancy test for women of child bearing potential
* stable function of the implanted device
* stable medical therapy relating to the underlying disease
* stable medical therapy of antiarrhythmic drugs and other QT-time changing drugs
* no instability of rhythm
* x-ray of thorax during device implantation in two levels (ap and ll axis)
* written informed consent
Exclusion Criteria
* patient with acute myocardial infarction or CABG while the last 4 weeks
* patient with tachycardia and a rest frequency \>80 bpm
* patient with severe pulmonary disease
* patient with anaemia
* patient with acute infections
* patient with severe kidney or liver disease
18 Years
75 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University of Magdeburg
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Dr. Samir Said
Dr. med.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Samir Said, Dr.
Role: PRINCIPAL_INVESTIGATOR
Magdeburg University
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Magdeburg University, Internal Medicine/Cardiology, Angiology and Pneumologie
Magdeburg, , Germany
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
OVGU-Kar-011
Identifier Type: -
Identifier Source: org_study_id